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We read with interest the recent 
article by Yoshimasu et al.1 which con-
cluded that lung cancers with epider-
mal growth factor receptor (EGFR) 
mutations were less sensitive to cis-
platin and docetaxel than those with 
wild-type EGFR based on histoculture 
drug response assays. As this is still a 
controversial issue,2,3 we would like to 
refer you to the results of our recent 
study in which we analyzed a panel of 
non-small cell lung carcinoma cell lines 
for genetic mutations; gene expression 
patterns; and sensitivities to cisplatin, 
paclitaxel, and gefitinib.4
We used a conventional cell 
growth inhibition assay in a 96-well for-
mat, and the results are shown in Figure 
1. our data showed that of the 40 non-
small cell lung cancer cell lines tested, 
EGFR mutants (n = 6) were relatively 
resistant to cisplatin. The IC50 of EGFR 
mutants ranged from 2.5 to 9.5 M. 
Two EGFR mutants, H1650 and H1975, 
showed IC50 values of 2.5 and 4.0 M, 
respectively, and four EGFR mutants 
(HCC827, HCC4006, PC3, and PC14) 
showed IC50 values for cisplatin more 
than 5 M. In our assay, paclitaxel was 
effective for most of the cell lines with 
IC50 values less than 0.1 M. However, 
there were four exceptional cell lines 
that were highly resistant to paclitaxel 
with IC50 values more than 10 M. of 
these four cell lines, two cell lines, PC3 
and PC14, harbored EGFR mutations 
and the other two, Calu3 and H1781, 
FIGURE 1. (A) Brain magnetic resonance image (MRI) before whole brain radiotherapy (WBRT); (B) Brain MRI 1 month after 
WBRT; (C) Brain MRI 1 month after the initiation of erlotinib.
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FIGURE 1. The IC50 values of the 40 non-small cell lung cancer cell lines for cispla-
tin according to the driver mutations and E-cadherin mRNA levels. Cell lines with 
low E-cadherin mRNA are shown in blue and cell lines with high E-cadherin mRNA 
are shown in red. Note that cell lines mutated for EGFR, HER2, MET, and BRAF 
express high levels of E-cadherin mRNA and are mostly resistant to cisplatin. KRAS 
mutants showed distinct sensitivities to cisplatin according to E-cadherin mRNA 
levels. Modified from Matsubara et al.4
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harbored HER2 amplifications and 
HER2 mutations, respectively. These 
results are mostly consistent with those 
of Yoshimasu et al.
Importantly, our study data also 
suggested that the sensitivity to cisplatin 
depended not only on EGFR mutations 
but also on other driver mutations the 
tumor harbored and on the epithelial- 
mesenchymal transition phenotype. 
For example, the EGFR mutant H1975, 
with some features of EMT,5 was 
relatively sensitive to cisplatin. Five 
cell lines with MET amplifications 
or HER2 abnormalities, all with high 
levels of E-cadherin mRNA, showed 
IC50 values similar to those of EGFR 
mutants. It was also of interest that 
KRAS-mutated cells with low levels 
of E-cadherin mRNA were more sensi-
tive to cisplatin, while KRAS-mutated 
cells with high levels of E-cadherin 
mRNA were highly resistant to cis-
platin (Figure 1). We did not find any 
correlations between ERCC1 and beta 
III tubulin expressions and sensitivities 
to cisplatin and paclitaxel, respectively 
(data not shown).
In light of our results, it would 
be more informative to analyze genetic 
abnormalities other than EGFR, as well 
as histologic features and E-cadherin 
expression, in the study by Yoshimasu 
et al. We would like to stress that EGFR 
wild-type tumors are actually hetero-
geneous tumors with regard to driver 
mutations, such as the KRAS mutation, 
HER2 mutation, ALK rearrangement, 
etc., and the EMT phenotype, and the 
proportion of these heterogeneous 
tumors may differ in different ethnic 
groups. Therefore, the results compar-
ing the EGFR-mutant and EGFR wild-
type tumors must be interpreted with 
caution.
In summary, we appreciate the 
work by Yoshimasu et al. regarding 
EGFR mutations and chemosensitivi-
ties, but we believe that genetic pro-
files other than the EGFR mutation 
and EMT phenotype need to be con-
sidered when analyzing sensitivities 
to chemotherapeutic agents, especially 
cisplatin.
Daisuke Matsubara, PhD, MD
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In Response:
We thank Dr. Matsubara and 
coworkers for their interest in our article 
and presenting their informative data. It 
is known that epidermal growth factor 
receptor (EGFR) mutation-positive and 
-negative tumors have different char-
acteristics. Therefore, we consider that 
chemosensitivity profiles for anticancer 
agents are not identical between EGFR 
mutation-positive and -negative tumors.
As Dr. Matsubara mentioned in his 
letter, EGFR mutation-negative tumors 
are heterogenous. Tumors with various 
driver mutations are included in this 
group. We also agree that tumors with 
different driver mutations have the pos-
sibility of showing different chemosensi-
tivity profiles. Their data clearly provide 
evidence for this issue.1
It is also important to be aware 
that these genetic alterations probably 
do not directly regulate chemosensitivity 
for anticancer agents, unlike ERCC1 and 
class-III β-tubulin.2,3 We surmise that the 
EGFR gene does not directly regulate 
chemosensitivity for docetaxel. our data, 
as well as Dr. Matsubara’s data, may only 
show that different cancers have differ-
ent chemosensitivity profiles.
The prognosis of patients with 
advanced non–small-cell lung cancer 
(NSCLC) highly depends on their EGFR 
mutation status. Therefore, the EGFR 
mutation status is now routinely tested in 
patients with NSCLC in clinical practice. 
This can be useful if the EGFR mutation 
status also provides some more informa-
tion regarding chemosensitivity for cyto-
toxic anticancer agents. our article has 
provided such data.
To investigate predictive markers 
for cancer chemotherapy, established 
cell lines are useful and powerful 
tools. However, this involves some 
limitations. Cell lines cannot be estab-
lished from all lung-cancer specimens. 
Usually they originate from a highly 
malignant subgroup, and then they 
involve a certain selection bias.4 our 
approach, based on the histoculture 
drug response assay, is a solution to 
reduce this selection bias.
It is unknown whether some driver 
mutations in NSCLC directly regulate 
chemotherapy responses. our histocul-
ture drug response assay–based approach 
does not seem to be suitable for investi-
gating this problem. Further investigation 
by Dr. Matsubara’s research group using 
an established cell-line panel might be 
helpful.
Tatsuya Yoshimasu, MD, PhD
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